TISIDB

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF08210 APOBEC-like N-terminal domain
Function	Probable C to U editing enzyme whose physiological substrate is not yet known. Does not display detectable apoB mRNA editing. Has a low intrinsic cytidine deaminase activity. May play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation.

> Gene Ontology [ TOP ]
Biological Process	GO:0006213 pyrimidine nucleoside metabolic process GO:0006216 cytidine catabolic process GO:0006304 DNA modification GO:0006397 mRNA processing GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009164 nucleoside catabolic process GO:0009451 RNA modification GO:0009972 cytidine deamination GO:0016556 mRNA modification GO:0019439 aromatic compound catabolic process GO:0034655 nucleobase-containing compound catabolic process GO:0035510 DNA dealkylation GO:0042454 ribonucleoside catabolic process GO:0044270 cellular nitrogen compound catabolic process GO:0044728 DNA methylation or demethylation GO:0046087 cytidine metabolic process GO:0046131 pyrimidine ribonucleoside metabolic process GO:0046133 pyrimidine ribonucleoside catabolic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046700 heterocycle catabolic process GO:0070988 demethylation GO:0072527 pyrimidine-containing compound metabolic process GO:0072529 pyrimidine-containing compound catabolic process GO:0080111 DNA demethylation GO:1901136 carbohydrate derivative catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process
Molecular Function	GO:0004126 cytidine deaminase activity GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016814 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines GO:0019239 deaminase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-75094: Formation of the Editosome R-HSA-74160: Gene Expression R-HSA-75072: mRNA Editing R-HSA-72200: mRNA Editing

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between APOBEC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of APOBEC2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.54	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of APOBEC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.337	0.21
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.373	0.487
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.31	0.474
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.436	0.29
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.247	0.833
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.683	0.674
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.043	0.919
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.474	0.493
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.615	0.402
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.705	0.41
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.705	0.539
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.141	0.441

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of APOBEC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APOBEC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APOBEC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APOBEC2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APOBEC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of APOBEC2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between APOBEC2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	APOBEC2
Name	apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2
Aliases	ARCD1; apolipoprotein B mRNA editing enzyme, catalytic polypeptide 2; mRNA(cytosine(6666)) deaminase 2; C->U ......
Chromosomal Location	6p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting APOBEC2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse APOBEC2